Intraocular pressure (IOP) peaks and means have been considered important factors for glaucoma onset and progression. However, peak IOP detection depends only on appropriated IOP checks at office visits, whereas the mean IOP requires longitudinal IOP data collection and may be affected by the interval between visits. Also, IOP peak assessment is necessary to verify if the peak pressure of a given patient is in target range, to evaluate glaucoma suspect risk, the efficacy of hypotensive drugs and to detect early loss of IOP control. The water-drinking test has gained significant attention in recent years as an important tool to evaluate IOP peaks and instability. The main objective of this review was to present new findings and to discuss the applicability of the water-drinking test in glaucoma management.
INTRODUCTION
Elevated intraocular pressure (IOP) and mean IOP are considered the main risk factors for the development and progression of glaucoma. [1] [2] [3] As a result, reduction of IOP to an individualized target is our main treatment strategy. The pressure at which glaucoma occurred, the target IOP and response to treatment are most often determined by a series of single measurements over time during office hours. However, some patients still progress with IOP apparently in the target range. This observation has been explained on the basis that other non-IOP-dependent risk factors are contributing to the glaucoma pathogenesis in these individuals. 4 An alternative explanation is that progression occurs because of high IOP peaks not detected during routine eye examinations. Although IOP fluctuation [5] [6] [7] is a suggested risk factor for glaucoma progression, recent studies have demonstrated that peak IOP may be a better predictor of glaucoma progression and more practical for management guidance. [8] [9] [10] Twenty-four-hour IOP monitoring is likely to provide the purest understanding of an individual's IOP control including mean IOP, IOP fluctuation and peak IOP. 11, 12 An inexpensive, non-invasive, time efficient and accurate means of measuring 24-h IOP is yet to become available. Current methods are time and resource-intensive and are not always feasible in routine practice. It is because of these limitations that the water drinking test (WDT) is so useful in glaucoma assessment and management.
The WDT was originally conceived as a diagnostic test for glaucoma but was ultimately abandoned for this purpose because of low sensitivity, low specificity and low diagnostic value. 13, 14 Recently, this test was revived with a new focus: as a surrogate marker for outflow facility reserve to detect IOP instability and to estimate IOP peak pressure. Peak IOP elicited by this test may be an indicator for the likelihood of progression 15, 16 and efficacy of hypotensive drugs. [17] [18] [19] [20] [21] Its potential was highlighted in the findings of the collaborative glaucoma study 22 in which 5886 eyes without glaucoma were followed for up to 13 years. Among the risk factors identify for new onset glaucoma, a WDT response exceeding 5 mmHg was associated with a sixfold increased risk compared with those with a WDT response less than 1 mmHg. This new concept led to a growing interest in the test. The WDT has been the subject of multiple editorials in peer-reviewed journals since 2008. [23] [24] [25] [26] [27] In an editorial about publication and citation in ophthalmology, the authors stated that the WDT had experienced a major and recent revival based on the fact that the 32 articles that included this test have been cited on average 10.26 times, which is a mean citation count above the normal and expected mean. 23 
HOW TO PERFORM A WATER DRINKING TEST
Eligible patients (i.e. those who are not on fluid restriction because of systemic conditions) liquid fast for 2 h before the WDT. The patient's baseline IOP is then measured following which the patient drinks a given volume of water in 5 min. The volume used has not been standardized. Some authors routinely use a fixed volume of water, whereas others use a volume adjusted to bodyweight.
A direct comparison between the ingestion of 1000 mL (33.8 ounces) or 500 mL (16.9 ounces) of water demonstrated that the latter failed to estimate the peak diurnal pressure. 28 It has been suggested that the WDT may be performed with 800 mL (27. showed that the peak of the WDT elicited when using 800 mL of water was significantly associated with the progression of openangle glaucoma. A dose of 10 mL of water/kg of bodyweight has also been used. 29, 30 This is an attempt to correct for the effect of body mass and shift of fluid between intravascular, intracellular and interstitial spaces. It is based on the presumption that a fixed volume, for example, 1000 mL, is likely to have a different physiological effect in a 100-kg patient compared with a 50-kg patient. Although based on sound principles, this has not been validated, although it is known to induce a significant IOP response that correlates to diurnal IOP peak as well as the ingestion of 800 mL, but not 500 mL.
Current preference is based in part on personal experience and also on scientific principles. Most recent studies use 800 mL or 10 mL/kg of bodyweight. Also, 2-h fasting time before the test is advised, in order to avoid any possible influence of previous liquid ingestion over the results. It is not yet clear whether the use of 1000 mL, 800 mL or 10 mL/kg bodyweight improves the correlation or predictive value of the WDT.
Once the water has been imbibed, the IOP is measured three to four additional times at 15-min intervals. 31 The baseline IOP is the IOP value measured immediately before water ingestion. The maximum value of the subsequent measurements is selected as the peak IOP during the WDT. The elevation in IOP may recover quickly or be sustained for the majority of the test.
MECHANISM OF ACTION
The mechanism of the IOP increase after a water overload remains unclear. Early work 32 focused on outflow resistance and suggested outflow facility does reduce, but the amount of reduction is small and in isolation may not explain the associated rise in IOP. A study published in 1972 33 showed intramuscular atropine suppressed the WDT response suggesting a potential centrally mediated mechanism.
Aqueous fluorophotometry and estimation of the episcleral venous pressure (EVP) using manometry following a 1000-mL WDT has been measured in young healthy volunteers. 34 Estimated EVP more than doubled within 10 min of the water load and was maintained at this level for 90 min at which time measurement was stopped. At the same time, increased fluorescein concentration was detected in aqueous at 10 min; this returned to baseline 60 min after the water load. The explanation for increased fluorescein concentration is uncertain, but it may represent negative flow or reflux of fluorescein from Schlemm's canal. These findings suggest a role for increased EVP in the WDT response and underlie the rationale for performing the test over 60 min as indicated in the previous discussion.
More recent work has focused on the role of choroidal expansion. [35] [36] [37] One study 35 reported an average 20% increase in choroidal thickness during the WDT in eyes with open angles; this finding was postulated to contribute to the IOP response. However, such a change in choroidal thickness has not been observed consistently and may occur more readily in eyes with angle closure. 36 
INTERPRETING RESULTS
Having performed a WDT with 1-h or 45-min follow up, five or four IOP readings (a baseline and four or three follow up) will be available for comparison. From this, several variables can be evaluated: the peak IOP, the IOP elevation (Peak IOP -baseline IOP), the time to peak IOP and time to recovery to baseline IOP.
Several studies have shown that peak IOP obtained with this test is strongly correlated and in agreement with the IOP peaks that occur during the day. 29, 38, 39 Usually but not always, eyes with higher IOP peaks after water ingestion take longer to return to baseline IOP levels than eyes with lower IOP peaks, which may reflect the status of the drainage system of the eye.
The factors influencing time to peak IOP following the WDT are less certain. This is because findings so far are inconsistent. For example, Mansouri et al. 37 reported that highest mean peak IOP from 58 healthy eyes occurred at 15 min. Distribution of peak IOP over time in this cohort was 46% at 15 min, 32% at 30 min, 14% at 45 min and 8% at 120 min. Similarly, Ulas et al. 40 have shown in healthy eyes that IOP elevation after WDT occurs within the first 10 min and recovers quickly. This is somewhat different from results with glaucomatous eyes. Tran et al. 41 reported mean peak IOP was highest at 45 min after water ingestion, whereas Hatanaka et al. 42 found that, on average, mean peak IOP was highest at 30 min, in a cohort of 88 eyes with ocular hypertension or primary open-angle glaucoma (POAG).
It has been postulated that a more rapid return to baseline IOP following the WDT may reflect improved outflow facility. 26 Independent of the mechanism that increases IOP following the WDT, an intact and active outflow facility should be associated with rapid IOP recovery, whereas impaired outflow facility is more likely to lead to sustained IOP elevations. The WDT response is more marked in angle closure eyes compared with open-angle eyes. 36 
CLINICAL AND RESEARCH APPLICATIONS
The WDT has applications for understanding how IOP-lowering treatments work and why glaucoma progresses. It is an aid to understand our patients' IOP and the way treatments control (or do not control) it.
Treatment
The WDT has been used to compare the effects of different clinical and surgical treatment modalities in glaucoma. Medically controlled patients with glaucoma have a greater IOP increase with the WDT than patients who have undergone filtration surgeries despite similar baseline IOP. 30, 31 The reason for this is not clear but may relate to the way a functioning trabeculectomy diverts aqueous away from conventional outflow pathways. The observation that trabeculectomy blunts the WDT response, and therefore IOP fluctuation and peak, may explain why filtering surgeries decrease or halt glaucoma progression compared with medical treatment. 31, 43, 44 The WDT has also been used to evaluate different hypotensive medications for glaucoma. In a comparison between latanoprost and the fixed combination of dorzolamide and timolol, patients who received latanoprost showed significantly smaller elevations in their IOP levels following the WDT. 17 These authors demonstrated that prostaglandin analogues that act on the outflow system of the eye are associated with better IOP stabilization during the WDT than drugs that decrease aqueous humour production, such as β-blockers and carbonic anhydrase inhibitors. Some drugs may demonstrate similar IOP reduction in steady-state situations but dissimilar effects on blunting IOP spikes that may occur during the day. For this reason, they may have an additional benefit on glaucoma treatment. 17, 18, 45 Although timolol 0.5% showed similar IOP reduction to brimonidine 2.0%, IOP was more stable on brimonidine than with timolol. Eyes treated with timolol had an earlier IOP spike, higher mean IOP peak (3.5 mmHg) and return to baseline took longer in the WDT. This may be an alternative explanation for the results of LoGTS, 46 in which, despite its limitations, especially regarding the highest dropout rate in the brimonidine group, similar IOP (single measurements) were obtained in both groups, whereas the rate of visual field progression was higher in the timolol group. Other studies compare the efficacy of IOP reduction between drugs or the benefit of adding drugs to a pre-existing therapeutic regimen and the mechanisms of action of hypotensive medications. [19] [20] [21] 47 To this, we can now add the findings of Waisbourd et al. 48 which suggest a role for the WDT in assessing response to peripheral laser iridotomy. Although no significant change in peak WDT IOP was reported before and after treatment of primary angle closure suspect eyes, a more rapid recovery in the WDT IOP curve was seen post-treatment. The authors postulate that this more rapid recovery is due to enhanced outflow facility that accompanies reduced iris -trabecular apposition.
Malerbi et al., 49 within a group of 65 patients with moderate open-angle glaucoma, based on visual field criteria, and IOP ≤ 15 mmHg at single office readings, found that 21.5% had IOP levels of >20 mmHg during the WDT, considered too high for a target IOP of 15 mmHg.
Eyes with worse visual field mean deviation values had higher IOP peaks after water ingestion compared with their contralateral eyes that had better visual fields despite similar mean baseline IOPs. 16 This suggests worse IOP control in the eye with lower mean deviation. This study also highlighted Water drinking test and glaucoma 627 that despite similar baseline IOP, eyes with similar visit-measured single IOP may have different peak IOP. This has been confirmed by other authors and has immediate clinical relevance. 27, 31, 50 IOP peak is an important factor for progression and usually not detected in routine clinical examination, which may explain at least in part why patients progress with 'low IOP measurements'.
Previous studies have also found a correlation between the WDT response and progressive damage. In a prospective study of 5886 patients with open-angle glaucoma, Armaly et al. 22 identified 5 of 26 potential risk factors that were significantly related to the development of visual field defects: outflow facility, age, IOP, cup-to-disc ratio and the change in IOP after water ingestion. Compared with single IOP measurements however, the response to WDT showed a weaker correlation. Of relevance, the authors assessed IOP change after water ingestion, and not IOP peaks. IOP fluctuation lacks reproducibility, and its role, as a predictor for progression has been debatable.
Despite presenting poor collective predictive power for visual field progression, IOP, cup-to-disc ratio and age remain important parameters in clinical practice. Hence, the importance to better evaluate the role of WDT as a tool in glaucoma management. In a sample of normotensive glaucomatous patients evaluated by Yoshikawa et al., 51 the WDT was the main predictive test for glaucoma progression. Even an increase of 1 mmHg in the IOP is associated with a 10% increase in the relative risk for glaucoma conversion 1 and visual field progression. 3, 52 To be considered clinically applicable, a test must present reproducible results. Reproducibility has already been evaluated in different populations and intervals between tests, both in terms of correlation and concordance. While correlation describes how strongly the measurements in each group resemble each other, concordance evaluates the agreement between the evaluated parameters (peaks and fluctuation).
Intraocular pressure peaks detected by the WDT, performed 24 h apart in untreated patients with ocular hypertension, showed excellent reproducibility (intraclass correlation coefficient). 42 The same was observed by the same research group, 53 in a cohort of treated POAG patients and mean interval of 4.85 (range 3-6) months between tests. In both studies, however, fluctuation showed only fair reproducibility. Babic et al. 53 hypothesize that, while similar IOP peaks lead to a 'ceiling effect', fluctuation, defined as maximum-minimum IOP, will depend on baseline IOP measurements, which, in turn, may present small differences due to variability between tests, thus leading to different starting baseline points and lower reproducibility parameters. The authors also stated that in clinical practice, the importance of detecting better repeatability of IOP peaks than fluctuation results from recent studies that found IOP peaks as the most important IOP parameter associated with glaucoma progression. [8] [9] [10] In both studies, reproducibility was also evaluated, based on levels of agreement. Hatanaka et al. 42 found that almost 80% of peak IOP measurements presented differences within 3 mmHg, (95% within ±5.7 mmHg), whereas Babic et al. 53 found almost 80% of IOP peak with differences within 2 mmHg (95% within À4.24 and +3.3 mmHg) between tests.
Medina et al. 54 evaluated the reproducibility of WDT performed at different times of the day in POAG and normal individuals. The authors, based on levels of agreement, state a poor reproducibility of IOP peaks detected by the test, because 20% of glaucoma patients presented differences higher or equal to 3 mmHg among IOP peaks at different tests. However, if this is the case, then 80% of their sample was, indeed, within 3 mmHg of agreement, a proportion of reproducibility close to the findings of Hatanaka et al. 42 and Babic et al. 53 Reproducibility of the WDT was also demonstrated in patients with exfoliation syndrome and exfoliative glaucoma. 55 It may be that patient's peak IOP is a constant and crucial clinical parameter, which is independent of initial IOP and underscores a patient's likelihood for future progression. 27 Other methods to evaluate IOP profile have been described. Self-monitoring of IOP with portable home tonometers [56] [57] [58] may reveal IOP peaks not detected during daytime tension curves. 58 However, validation of these devices for this purpose is still needed. Costs and labour to perform 24-h daily tension curves on all patients are prohibitive. A shorter daytime tension curve and single IOP measurements in several days are more practical but may miss IOP peaks in 70% of cases. 59, 60 Continuous 24-h IOP monitoring may also be obtained with the Triggerfish contact lens sensor (Sensimed AG, Lausanne, Switzerland). The device measures the IOP indirectly, by capturing circumferential changes at the corneoscleral area. When comparing the contact lens sensor with a diurnal tension curve performed with a pneumatonometer, similar IOP peak timing was demonstrated by both methods, whereas no correlation was found in terms of 24-h IOP variation. 61 The Eyemate (Implandata Ophthalmic Products GmbH, Hanover, Germany) can only be used in patients submitted to cataract surgery. The accuracy of the IOP measurements is still not established, as well as its clinical significance. Cost and risks make the device not practical and difficult to be used in all patients.
CONCLUSION
There has been an increased value attributed to the occurrence of IOP peaks as risk factors for glaucoma onset and progression, 9, 10 and more interest has developed to establish a target IOP peak or target IOP peak range pressure instead of a single target IOP level. Future studies of methods to better evaluate the IOP profile over a 24-h period are warranted. While special devices for continuous IOP monitoring are being analysed, their practical use on a daily basis and in high-volume outpatient settings over a shortterm period remains uncertain. The measurements given by the Triggerfish lens device (Sensimed, Lausanne, Switzerland) have not corresponded to the IOP measured in mmHg and also can be influenced by biomechanics of the cornea such as corneal curvature, central cornea thickness and hysteresis. 62 Some side effects such as corneal oedema, hyperemia and discomfort have also been associated with its use. Meanwhile, the WDT is reproducible and shows clinically relevant results validated several times by a series of peer-reviewed studies; it can be an important tool for IOP profile assessment in glaucoma management.
The WDT cannot be used for the diagnosis of glaucoma; there are no positive or negative results as in the past. The WDT may be used as a stress test to evaluate the ability of the eye to deal with transient IOP elevations and the peak IOP elicited by this test strongly correlates to IOP peaks that occur during the day. For this reasons, it may be an important tool to evaluate the quality of hypotensive treatment and to detect early loss of IOP control.
One limitation of this review is the retrospective design of the majority of the previously mentioned studies. Based on this revision, one could speculate that the inclusion of this test as part of a routine examination, could improve IOP monitoring and risk assessment, which, in turn, could lead to better outcomes in glaucoma management. This concept, however, is indirect and based on all the evidences discussed in this review. Prospective studies to further enhance this concept are awaited.
